Inspire Medical Systems, Inc. Stock 12‑Month Price Target Raised to $69.31, Implies 3% Upside

Inspire Medical Systems' average stock price target increased from $68 to $69.31 by 16 analysts, implying 3% upside from Nov. 2 close. 19 analysts maintain 'Hold' consensus, with 4 'Buy' and 4 'Sell' ratings.

Original reporting
Published Nov 3, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Inspire Medical Systems, Inc. Stock 12‑Month Price Target Raised to $69.31, Implies 3% Upside — source image
Decision brief

The 30-second read

$INSPNeutralLow
01

Why it matters

A small increase in the average price target suggests incremental optimism, but the consensus rating staying at Hold implies limited immediate re-positioning.

02

Market read

Useful for tracking sentiment and target drift, but not a standalone catalyst for trading decisions.

03

What to watch

Because the article provides no new clinical, regulatory, or financial datapoint, traders may treat it as noise versus upcoming company-specific catalysts.

Relevance 4/10Novelty 4/10Timing: today’s analyst-target update (no scheduled event)

Background

The piece summarizes FactSet-derived consensus analyst targets and ratings for Inspire Medical Systems.

Company-level read

Ticker impact

$INSPNeutralMedium confidence
Context

Inspire Medical Systems’ average analyst price target rose from $68 to $69.31, with consensus rating still “Hold.”

Expected impact

Likely mild support as traders price in slightly higher targets, but follow-through may be capped by the unchanged Hold rating.

Evidence & confidence

This is an analyst-target update without new company fundamentals, and the consensus remains Hold despite some Buys and Sells.

Market effects

Limited read-through to medical device peers because the update is purely analyst-target related, not a sector catalyst.

No clear regional spillover implied.

No global macro or cross-market linkage indicated.

Counterpoint

The higher average target may reflect dispersion (range $40 to $97) rather than a coherent re-rating, so price may not follow.

Key entities

  • Inspire Medical Systems, Inc.

    Subject of the article, with average analyst price target raised to $69.31 and consensus rating remaining Hold.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.